All In MedTech

Device Trial Radar · NCT00189592

Plantar Fasciosis Treatment Using Coblation

Plantar Fasciosis Treatment Using Coblation® Prospective, Double-Blind, Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: Aug 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Aug 2005

Primary completion

Jun 2008

Study completion Jun 2008

Sponsor

Lead sponsor
ArthroCare CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2005

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 72 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of Coblation-based fasciotomy for relieving pain associated with recurring plantar fasciosis and, secondarily, to determine whether there may be additional potential benefits stemming from its use.

Conditions

  • Plantar Fasciitis

Interventions

  • ArthroCare TOPAZ™ MicroDebrider™ using CoblationDevice

    Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.

  • Surgical FasciotomyProcedure

    Standard surgical fasciotomy using an incision to treat the plantar fascia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain reliefTime frame: at 24 hours, 48 hours, 7 to 14 days, 4 to 6 weeks, 3 months, 6 months, 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Weil Foot & Ankle Institute

    Des Plaines, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.